Key EscharEx Phase III Trial Delayed by a Quarter; MediWound Q1 Revenue Missed Estimates
MDWD is trading near its 52-week low of $14.14 (1.3% above the low) on elevated volume (5.3× avg).
Summary
MediWound announced a delay of approximately one quarter for the enrollment completion of its pivotal EscharEx Phase III VALUE trial, now targeting end of Q1 2027. This follows the Q1 2026 earnings report from May 27th, which confirmed revenue of $1.5 million, significantly missing analyst expectations. The delay in a key late-stage clinical trial for EscharEx is a material setback, pushing back the potential timeline for market entry and future revenue generation. This news adds further pressure following the company's reported financial underperformance.
At the time of this announcement, MDWD was trading at $14.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $184.1M. The 52-week trading range was $14.14 to $22.51. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.